PRME
Price
$1.30
Change
-$0.02 (-1.52%)
Updated
May 9 closing price
Capitalization
170.68M
ZLAB
Price
$29.24
Change
+$0.10 (+0.34%)
Updated
May 9 closing price
Capitalization
3.33B
93 days until earnings call
Ad is loading...

PRME vs ZLAB

Header iconPRME vs ZLAB Comparison
Open Charts PRME vs ZLABBanner chart's image
Prime Medicine
Price$1.30
Change-$0.02 (-1.52%)
Volume$1.39M
Capitalization170.68M
Zai Lab
Price$29.24
Change+$0.10 (+0.34%)
Volume$1.44M
Capitalization3.33B
PRME vs ZLAB Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. ZLAB commentary
May 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and ZLAB is a Hold.

Ad is loading...
COMPARISON
Comparison
May 10, 2025
Stock price -- (PRME: $1.30 vs. ZLAB: $29.24)
Brand notoriety: PRME and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 90% vs. ZLAB: 117%
Market capitalization -- PRME: $170.68M vs. ZLAB: $3.33B
PRME [@Biotechnology] is valued at $170.68M. ZLAB’s [@Biotechnology] market capitalization is $3.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileZLAB’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • ZLAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ZLAB is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 3 TA indicator(s) are bullish while ZLAB’s TA Score has 5 bullish TA indicator(s).

  • PRME’s TA Score: 3 bullish, 5 bearish.
  • ZLAB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ZLAB is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -22.62% price change this week, while ZLAB (@Biotechnology) price change was -6.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.25%. For the same industry, the average monthly price growth was +9.40%, and the average quarterly price growth was -13.49%.

Reported Earning Dates

PRME is expected to report earnings on May 08, 2025.

ZLAB is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-6.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLAB($3.33B) has a higher market cap than PRME($171M). ZLAB YTD gains are higher at: 11.646 vs. PRME (-55.479). PRME has higher annual earnings (EBITDA): -196.34M vs. ZLAB (-242.99M). ZLAB has more cash in the bank: 780M vs. PRME (190M). PRME has less debt than ZLAB: PRME (40.8M) vs ZLAB (153M). ZLAB has higher revenues than PRME: ZLAB (399M) vs PRME (2.98M).
PRMEZLABPRME / ZLAB
Capitalization171M3.33B5%
EBITDA-196.34M-242.99M81%
Gain YTD-55.47911.646-476%
P/E RatioN/AN/A-
Revenue2.98M399M1%
Total Cash190M780M24%
Total Debt40.8M153M27%
FUNDAMENTALS RATINGS
PRME vs ZLAB: Fundamental Ratings
PRME
ZLAB
OUTLOOK RATING
1..100
6655
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
6543
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
58n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (38) in the null industry is in the same range as ZLAB (49) in the Biotechnology industry. This means that PRME’s stock grew similarly to ZLAB’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ZLAB (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ZLAB’s over the last 12 months.

ZLAB's SMR Rating (96) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that ZLAB’s stock grew similarly to PRME’s over the last 12 months.

ZLAB's Price Growth Rating (43) in the Biotechnology industry is in the same range as PRME (65) in the null industry. This means that ZLAB’s stock grew similarly to PRME’s over the last 12 months.

ZLAB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that ZLAB’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMEZLAB
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 4 days ago
80%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-1.52%
CRSP - PRME
62%
Loosely correlated
-1.44%
RXRX - PRME
58%
Loosely correlated
-1.37%
BEAM - PRME
57%
Loosely correlated
+0.93%
NTLA - PRME
54%
Loosely correlated
-1.93%
ALLO - PRME
52%
Loosely correlated
-1.69%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
+0.34%
ONC - ZLAB
41%
Loosely correlated
-1.67%
PRME - ZLAB
38%
Loosely correlated
-1.52%
VERV - ZLAB
35%
Loosely correlated
-5.58%
ABCL - ZLAB
34%
Loosely correlated
+1.00%
ATXS - ZLAB
34%
Loosely correlated
-3.86%
More